Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection ...

If repeat Hep B surface antibody titer is non-reactive, a Hep B surface antigen test is required to rule out acute or chronic Hepatitis B infection. If Hep B surface antigen test is negative, student ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...

A study to determine the extent of such blood-borne infections in the community also found that the prevalence of Hepatitis B and HIV was 'significantly higher' in the Cork region ...

Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

Interference with Laboratory Tests Hepatitis B surface antigen (HBsAg) derived from hepatitis B vaccines has been transiently detected in blood samples following vaccination. Serum HBsAg detection ...

These additions include single-gene sequencing for seven different cancers, hepatitis B core-related antigen (HBcrAg), and surface antigen quantitative tests, and the Ozaki procedure for aortic ...

Thirty-four HBsAg tests were performed on 34 different patients within 14 days of a dose of Engerix-B® hepatitis B vaccine, with 24 of these occurrences involving patients with chronic renal ...